OnKure Therapeutics (OKUR) Insider Trading & Ownership $3.00 -0.04 (-1.32%) Closing price 04:00 PM EasternExtended Trading$3.00 +0.00 (+0.17%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OnKure Therapeutics (NASDAQ:OKUR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage17.90%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$11,749.08 Get OKUR Insider Trade Alerts Want to know when executives and insiders are buying or selling OnKure Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address OKUR Insider Buying and Selling by Quarter Remove Ads OnKure Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/7/2025Jason A LeveroneCFOSell1,844$2.67$4,923.48 4/7/2025Nicholas A SaccomanoCEOSell516$2.67$1,377.72 4/4/2025Jason A LeveroneCFOSell1,278$3.33$4,255.74 4/4/2025Nicholas A SaccomanoCEOSell358$3.33$1,192.14 (Data available from 1/1/2013 forward) OKUR Insider Trading Activity - Frequently Asked Questions Who is on OnKure Therapeutics's Insider Roster? The list of insiders at OnKure Therapeutics includes Jason A Leverone, and Nicholas A Saccomano. Learn more on insiders at OKUR. What percentage of OnKure Therapeutics stock is owned by insiders? 17.90% of OnKure Therapeutics stock is owned by insiders. Learn more on OKUR's insider holdings. Which OnKure Therapeutics insiders have been selling company stock? The following insiders have sold OKUR shares in the last 24 months: Jason A Leverone ($9,179.22), and Nicholas A Saccomano ($2,569.86). How much insider selling is happening at OnKure Therapeutics? Insiders have sold a total of 3,996 OnKure Therapeutics shares in the last 24 months for a total of $11,749.08 sold. More Insider Trading Tools from MarketBeat Related Companies CGC Insider Transactions NGNE Insider Transactions DBVT Insider Transactions FULC Insider Transactions ACTU Insider Transactions RZLT Insider Transactions TARA Insider Transactions DMAC Insider Transactions IKT Insider Transactions PBYI Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Beware of BigBear.ai: Insiders Are Selling—Should You?Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldJoby Aviation: Operational Momentum vs. Market SentimentMicroStrategy Sees Insider Buy-Sell Action in Q1Casey’s General Stores Insider Buys Shares of This Must-Own Stock This page (NASDAQ:OKUR) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
